IGM Biosciences Inc . (NASDAQ:IGMS) stock has tumbled to a 52-week low, reaching a price level of just $1.59 USD. With a ...

IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% ...

IGM Biosciences (IGMS) announced a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 ...

NASDAQ IGMS opened at $2.09 on Friday. IGM Biosciences has a 1-year low of $1.87 and a 1-year high of $22.50. The company has a market capitalization of $124.28 million, a price-to-earnings ratio ...

IGM Biosciences had a negative return on equity of 155.42% and a negative net margin of 7,534.03%. Analysts forecast that IGM Biosciences will post -3.33 EPS for the current year. Hedge Funds ...

IGM Biosciences has halted all oncology programs and faces a significant pipeline upheaval, leading to a greater-than-50% drop in share price. Despite holding substantial liquid assets and a ...

Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory ...

Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all clinical development of drugs in its autoimmune franchise ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Stock tumbles to continue slide that started after the company switched to autoimmunity from oncology late last year IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after ...